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ABSTRACT
Background: Prostate cancer antigen 3 (PCA3) is a prostate cancer diagnostic 
biomarker that has been clinically validated. The limitations of the diagnostic role 
of PCA3 in initial biopsy and the prognostic role are not well established. Here, we 
elucidate the limitations of tissue PCA3 to predict high grade tumors in initial biopsy.
Results: PCA3 has a bimodal distribution in both biopsy and radical prostatectomy 
(RP) tissues, where low PCA3 expression was significantly associated with high grade 
disease (p<0.001). PCA3 had a poor performance of predicting high grade disease 
in initial biopsy (GS≥8) with 55% sensitivity and high false negative rates; 42% 
of high Gleason (≥8) samples had low PCA3. In RP, low PCA3 is associated with 
adverse pathological features, clinical recurrence outcome and greater probability of 
metastatic progression (p<0.001).
Materials and Methods: A total of 1,694 expression profiles from biopsy and 10,382 
from RP patients with high risk tumors were obtained from the Decipher Genomic 
Resource Information Database (GRIDTM)prostate cancer database. The primary 
clinical endpoint was distant metastasis-free survival for RP and high Gleason grade 
for biopsy. Logistic regression analyses and Cox proportional hazards models were 
used to evaluate the association of PCA3 with clinical variables and risk of metastasis.
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Conclusions: There is high prevalence of high grade tumors with low PCA3 
expression in the biopsy setting. Therefore, urologists should be warned that using 
PCA3 as stand-alone test may lead to high rate of under-diagnosis of high grade 
disease in initial biopsy setting.
INTRODUCTION
Prostate cancer (PCa) accounts for approximately 
23% of all male cancers, and 9% of all cancer deaths 
among men in Europe and in Northern America [1]. 
Only a subset of these patients may harbor aggressive 
disease with potential recurrence after first-line 
treatment. To improve patient management, it is 
essential to use accurate, quantitative tools (i.e genomic 
biomarkers) to identify patients with aggressive disease. 
Several recent studies have demonstrated the utility of 
protein coding and non-coding genes as prognostic and 
diagnostic biomarkers [2–4]. In particular, a number of 
long non-coding RNAs (lncRNAs) including Prostate 
cancer antigen 3 (PCA3), PCATs and SCHLAP1 
have emerged as attractive diagnostic or prognostic 
biomarkers [3, 5, 6].
PCA3 is over-expressed in 95% of prostate 
cancers, with up to 100-fold up-regulation compared 
to adjacent non-neoplastic cells [7]. PCA3 is also 
over-expressed in high-grade prostatic intraepithelial 
neoplasia [8–10]. In clinical practice, urine-based PCA3 
testing has been shown to outperform the diagnostic 
ability of Prostate Specific Antigen (PSA) in men with a 
prior negative biopsy [11, 12] resulting in FDA approval 
for clinical use for this indication [13]. Urinary PCA3 
showed similar performance in initial biopsy setting 
[14–16]. However, the diagnostic performance of PCA3 
in initial biopsy setting has led to high rate of under-
diagnosis of high grade disease where PCA3 had a 
sensitivity of 42% with a high false negative rate using 
a cut-off of 60 [16]. In 463 european men scheduled for 
repeat biopsy, 27 (21%) cancers with a Gleason score of 
7–9 would have been missed using a cut-off of 35 [11]. 
Similarly, PCA3 failed to predict high grade cancers 
with magnetic resonance imaging (MRI) suspicion 
score (mSS4-5) in the initial biopsy [17]. These studies 
illuminate the potential limitations of using urinary 
PCA3 as a diagnostic biomarker and suggest that some 
patients with low PCA3 may harbor aggressive disease 
at initial biopsy.
In the background of the established clinical role of 
PCA3, the limitations of PCA3 in the initial biopsy setting 
and the clinical and prognostic utility of tissue PCA3 in 
radical prostatectomy (RP) setting has not been reported 
in large cohorts. In this study, we quantify the expression 
of PCA3 in a large (n=12,076) localized prostate cancer 
cohort and relate these data to clinicopathological 
parameters, generating, to our knowledge, the largest 
study that correlates PCA3 expression to prostate cancer 
clinical outcome.
RESULTS
Expression of PCA3 in primary prostate 
cancer tissue
Previous studies have evaluated PCA3 in urine [11, 
12], yet the characteristics of PCA3 expression in prostate 
tissue remain under studied [18]. To begin to explore 
the prostate-specific expression of PCA3, we evaluated 
publically available The Cancer Genome Atlas (TCGA) 
data finding that while PCA3 was expressed in very few 
samples from other cancers, it was most abundant in 
prostate cancer (Figure 1A).
To expand our initial observations regarding the 
expression of PCA3 in prostate cancer, we used an array-
based approach to profile a large cohort of 8,532 and 1,694 
prostate tumors from prospective RP and biopsy tissues, 
respectively. For this analysis, we included the well-
characterized lncRNA SCHLAP1 as control for high grade 
prostate cancer [3]. As expected, we observed a strong 
right skewed distribution for SCHLAP1, confirming the 
reported expression pattern of this gene in prostate cancer 
(Figure 1B) [3]. In stark contrast, PCA3 demonstrated a 
bimodal distribution where 23% and 29% of patients were 
categorized as having low PCA3 (≤ 1.3) in biopsy and RP 
samples respectively (Figure 1B-1C). Gene with bimodal 
distribution exhibit mainly either high or low expression with 
small proportion with intermediate expression, unlike normal 
distribution in which most patients express intermediate 
expression. This observation was validated using a 
retrospective cohort of 1,850 patient expression profiles from 
the Decipher GRID database (Supplementary Figure 2). This 
bimodality could be a result of tumor cells going through a 
differentiation process and change of cellular state.
To interpret this observation in the context of 
prostate cancer genomics, we hypothesized that ERG 
fusion may be driving the expression of PCA3. However, 
PCA3 displayed a bimodal distribution in both ERG+ 
and ERG- tumors, as determined previously by our group 
[19], suggesting that the observed bimodal distribution is 
independent of ERG expression (Figure 1D).
High grade tumors in biopsy tissues have low 
PCA3 expression
To interpret the bimodal distribution clinically, we 
first investigated if PCA3 bimodality related to Gleason 
score in 1,694 initial biopsy samples from the Decipher 
GRID database. We found PCA3 was significantly 
associated with Gleason group (Spearman’s correlation: 
-0.15, p<0.001) where high Gleason group (Group 4&5) 
tumors showing lower expression of PCA3 (Figure 2A). 
Oncotarget50806www.impactjournals.com/oncotarget
Out of 234 samples with Gleason group 4&5, 105 
(44.8%) had low PCA3 levels which was significantly 
higher than 18% (out of 1228) Gleason groups (1&2) 
(Fisher’s test p <0.001). Out of 93 samples with Gleason 
group 5, the percentage of low PCA3 reached 58%. 
These results indicate that PCA3 is a poor predictor of 
high grade disease in biopsy with sensitivity of 55% and 
false negative rate of 44.8% in high grade tumors.
Low PCA3 in RP tissues is associated with 
adverse pathological variables
Next, we investigated if low PCA3 relates to 
clinicopathological variables at RP. In the prospective 
cohort (n=8,532) and pooled retrospective cohort 
(n=1,850), we found low PCA3 to be associated with high 
Gleason grades (groups 4&5) (Spearman’s correlation: 
Figure 1: Pan-cancer and prostate-specific expression of PCA3. A. TCGA Pan cancer analysis showing PCA3 to be PCa specific. 
B. Distribution of PCA3 (red) and SChLAP1 (blue) expression in prospective RP (B) and in biopsy C. showing that PCA3 has a bimodal 
distribution unlike SChLAP1 that is right skewed. D. Distribution of PCA3 in ERG+ and ERG- tumors as determined by our group 
previously [19] in prospective RP cohort.
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-0.18, p<0.001) (Figure 2B). In the prospective cohort, out 
of 1,790 patients in the Gleason groups 4&5, 763 (42%) 
have low PCA3. These results confirmed high levels of 
PCA3 was a poor predictor of high grade disease and 
low PCA3 levels was not an indication of the absence of 
cancer.
Distribution plots of PCA3 across Gleason groups 
showed Gleason groups 1 and 2 had a right modal 
distribution for PCA3, while group 5 (GS 9-10) had left 
modal distribution, in both the prospective biopsy (Figure 
2C), prospective RP (Figure 2D) and retrospective RP 
cohorts (Supplementary Figure 3). The distributions for 
GS 4+3 and GS 8 were bimodal, however, the bimodal 
distribution for GS 3+4 was skewed to the right (Figure 
2C). These data suggest the expression of PCA3 
expression in prostate tissue may reflect the differentiation 
status of tumors, correlated with the amount of pattern 4 
tumor present in tumors with mixed Gleason grade.
Next, we explored the association of PCA3 
expression (low vs. high) with pathological tumor 
characteristics, including pathological stage and Gleason 
group (Table 1). In the prospective, Gleason group 5 
(Odd Ratio (OR): 3.88, 95% Confidence Interval (CI): 
3.09-4.86, p<0.001) when compared to group 1, Seminal 
Vesicle Invasion (SVI) (OR: 2.12 [1.89-2.39], p<0.001), 
Extra Prostatic Extension (EPE) (OR: 1.59 [1.44-1.75], 
p<0.001) and Lymph Node Invasion (LNI) (OR: 2.14 
[1.72-2.66], p<0.001) were significantly associated with 
low PCA3 on Univariable Analysis (UVA). Similar results 
were obtained using the retrospective cohort (Table 1). 
Using Multivariable Analysis (MVA) logistic regression, 
EPE, SVI and Gleason group 5 remained significantly 
associated with PCA3 expression in the prospective and 
retrospective cohorts (Table 1). The negative correlation 
between PCA3 expression and Gleason scores was also 
observed in urinary samples (n=50) (Supplementary 
Figure 4) where PCA3 expression was measured using 
the same Human Exon arrays used for PCA3 expression 
measurement in RP and biopsy tissues.
Figure 2: Associations of PCA3 expression and pathological characteristics at RP. A. PCA3 expression across Gleason groups 
(1-5) in biopsy samples (n=1,694) and B. RP samples (n=8,532) showing that around 50% of Gleason 5 group have low PCA3. C-D. 
Distribution of PCA3 across Gleason groups in biopsy (C) and RP samples (D) showing GS5 to be more enriched with low PCA3 while 
GS1 enriched more with high PCA3.
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Low PCA3 expression tracks with poor prognosis 
and metastasis after RP
To assess the association of PCA3 expression with 
clinical endpoints we plotted PCA3 expression in a John 
Hopkins Medical Institute (JHMI) cohort previously used 
to validate the Decipher test (JHMI-I) [20] and tagged 
events for biochemical recurrence (BCR), metastasis 
(MET) and Prostate Cancer Specific Mortality (PCSM) 
free survival (Figure 3A). Here, we observed patients with 
low PCA3 expression had lower 5-year BCR free survival 
rates (58%), 5-year MET free survival rates (75%) and 10-
year PCSM free survival (85%) compared to high PCA3 
patients in JHMI-I cohort (76, 92, 96% for BCR, MET and 
PCSM respectively) (Figure 3A, Supplementary Table 3). 
A similar trend was observed in the Mayo-Clinic II cohort 
that was used to validate Decipher test (Supplementary 
Table 3).
In a set of 665 patients pooled from two cohorts 
[21, 22] and the subcohorts of two previously published 
Table 1: Univariable and multivariable analysis associating clinicopathologic risk factors with PCA3 in prospective 
(n=8,532) and retrospective cohorts (n=1,850)
Prospective data (n=8,532)
UVA MVA
Estimate(95% CI) p value Estimate (95% CI) p value
pre-PSA (ref: <10 ng/ml) 1.21 (1.05-1.4) 0.008 0.91 (0.78-1.07) 0.26
EPE 1.59 (1.44-1.75) <0.001 1.24 (1.07-1.43) 0.005
SVI 2.12 (1.89-2.39) <0.001 1.61 (1.35-1.92) <0.001
SM 0.98 (0.89-1.08) 0.73 0.97 (0.85-1.12) 0.69
LNI 2.14 (1.72-2.66) <0.001 1.42 (1.05-1.91) 0.02
Gleason group 2 (ref: 
group 1) 1.21 (0.99-1.49) 0.07 1.1 (0.77-1.57) 0.6
Gleason group 3 (ref: 
group 1) 1.96 (1.59-2.41) <0.001 1.58 (1.1-2.27) 0.01
Gleason group 4 (ref: 
group 1) 2.33 (1.83-2.96) <0.001 1.83 (1.23-2.72) 0.003
Gleason group 5 (ref: 
group 1) 3.88 (3.09-4.86) <0.001 2.83 (1.93-4.15) <0.001
Pooled retrospective data (n=1,850)
UVA MVA
Estimate (95% CI) p value Estimate (95% CI) p value
pre-PSA (ref: <10 ng/ml) 0.9359(0.756-1.158) 0.542 0.8036(0.638-1.012) 0.064
EPE 1.3662(1.112-1.679) 0.003 1.1358(0.901-1.433) 0.282
SVI 1.6435(1.312-2.059) <0.001 1.3382(1.031-1.737) 0.028
SM 0.8033(0.659-0.979) 0.030 0.7931(0.640-0.983) 0.035
LNI 1.8508(1.353-2.532) <0.001 1.2657(0.887-1.807) 0.194
Gleason group 2&3 (ref: 
group 1) 0.9361(0.699-1.253) 0.657 0.9123(0.651-1.278) 0.593
Gleason group 4 (ref: 
group 1) 1.8648(1.272-2.734) 0.001 1.7886(1.177-2.718) 0.006
Gleason group 5 (ref: 
group 1) 2.1513(1.542-3.001) <0.001 1.951(1.320-2.883) <0.001
pre-PSA: preoperative prostate specific antigen; EPE: extra prostatic extension; SVI: seminal vesicle invasion; SM: surgical 
margins; LNI: lymph node invasion.
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case cohorts [20, 23], we found patients with high PCA3 
had nearly 50% lower risk of developing metastasis at 
5-years, compared to those with low PCA3 (Hazard Ratio 
(HR): 0.56 (95% CI: 0.43-0.72, p<0.001) (Figure 3B). 
Kaplan-Meier analysis showed that low PCA3 is 
significantly associated with early metastasis after radical 
prostatectomy in both the JHMI-I (HR: 0.35, 95% CI: 
0.22-0.57, p<0.001) and Mayo-Clinic II (HR: 0.45, 95% 
CI: 0.26-0.79, p=0.005) datasets (Figure 3C, 3D). In the 
prospective RP cohort outcome data are currently not 
available, making it difficult to assess the prognostic 
impact of PCA3. However, in previous work we have 
demonstrated a robust correlation between Decipher 
risk categories and metastasis [20]. As such, we used the 
Figure 3: Prognostic impact of PCA3 in localized prostate tumors. A. Waterfall plot of PCA3 with clinical endpoint annotations. 
BCR, biochemical recurrence; MET, metastasis, PCSM, PCa-specific mortality. B. Association between probability of 5-year metastasis 
and PCA3 expression in 665 samples pooled from two cohorts [21, 22] and the subcohorts from two case cohorts (JHMI-I, Mayo-Clinic 
II) [20, 23]. C-D. Kaplan Meier analysis in two case-cohorts from JHMI-I and Mayo-Clinic II. PCA3 expression was categorized into low 
vs high. E. Association between Decipher risk categories and PCA3 levels showing low PCA3 patients are more enriched with high risk 
Decipher.
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frequency of Decipher risk categories as a surrogate for 
metastasis (low, intermediate vs high risk) across PCA3 
expression pentiles (5 categories of PCA3 expression 
each with 20% of samples). Using these metrics, we 
observed 56% and 33% of patients with high Decipher 
showed low and high PCA3 expression, respectively 
(Fisher’s test, p<0.001) (Figure 3E). Interestingly, one of 
the top positively correlated genes across 8,532 samples is 
PCAT-14 (R=0.32, p<0.0001), which has also a bimodal 
distribution (Supplementary Figure 5) and has shown 
to increase migration [5]. Additional analysis found 
genes negatively correlated to PCA3 expression were 
enriched in gene sets related to epithelial-to-mesenchymal 
transition (EMT) based on Gene Set Enrichment Analysis 
(Supplementary Figure 6). Collectively, these data 
provide supporting evidence indicating lower PCA3 
levels correlate with a higher risk of metastasis and more 
aggressive prostate cancer at RP and biopsy setting.
DISCUSSION
The clinical utility of the PCA3 has been established 
as an independent diagnostic biomarker to predict prostate 
cancer in initial and repeat biopsy setting, primarily 
through urine-based analyses [6, 14]. However, the 
performance of PCA3 in initial biopsy setting has been 
shown in several studies to be poor with high false 
negative rate and low sensitivity rate leading to under-
diagnosis of high grade disease [11, 16, 24]. Additionally, 
establishing the prognostic significance of the same assay 
has been challenging, in part due to small cohort sizes.
In this study, we utilize the large collection of biopsy 
and RP expression profiles from the Decipher GRID 
database (GenomeDx Biosciences Inc.) to study PCA3 
expression and link it to clinical data and differentiation 
levels of tumor. We found that PCA3 demonstrated a 
striking bimodal distribution in prostate tissues representing 
distinct differentiation levels, which was not associated 
with ERG status and is distinct from other prostate specific 
prognostic lncRNA (i.e SChLAP1) that is right skewed. 
These data suggest PCA3 expression may be indicating two 
distinct differentiation cellular or tissue states within the 
prostate tumor; an early state where high levels of PCA3 are 
detectable and a second, late stage state where PCA3 levels 
decline. The bimodal expression pattern suggests unique 
biology for PCA3 which is not consistent with a ramping 
up of expression, as was observed for SCHLAP1. This 
observation motivated us to further understand the biology 
and clinical implication of PCA3 cycle.
We have associated PCA3 with Gleason scores in 
large biopsy and RP cohorts from the Decipher GRID 
and found patients with high Gleason have lower PCA3 
expression (42-45%). These results indicate that most 
patients with high Gleason would have been reported 
negative on diagnostic biopsy if PCA3 biomarkers was 
used for initial diagnosis. Moreover, in the prospective 
cohort from Decipher GRID (RP, biopsy) where metastatic 
outcome was not available, we found that low PCA3 was 
strongly associated with high risk Decipher scores and was 
a surrogate for metastasis. Additional analyses showed that 
genes negatively correlated with PCA3 are associated with 
migration pathways such as EMT. Based on expression 
correlation, PCAT-14 was the top correlated genes. In a 
recent report [5], In-vitro analysis showed that low PCAT-
14 expression increased migration while overexpressing 
PCAT-14 reduced cellular growth, migration, and invasion. 
These results suggest that patients with low PCA3 are at a 
significantly higher risk of developing metastasis after RP.
Recent work [25, 26] proposed that targeting PCA3 
may be a putative therapeutic option to inhibit PCa growth 
based on interfering siRNA in LNCaP and PC3 cells. These 
results are contradicting our observation possibly due the 
different nature of genomics of LNCaP cells and RP/biopsy 
tissues (used in this cohort) and different AR-activity in 
these specimens. We observed strong positive correlation 
between PCA3 and ABCC4, KLK2 and KLK3 that are AR 
target genes supporting the modulatory effect between AR 
and PCA3. Activated androgen receptor (AR) also strongly 
induces PCA3 transcription [26, 27]. We believe that the 
interaction between AR-axis induced by testosterone and 
PCA3 may significantly elucidate the functional impact 
of PCA3. Low pre-treatment free testosterone levels, are 
significantly associated with tumor grade and stage, with 
lower testosterone levels in patients with high grade PCa 
[27]. Prostate cancer patients with lower circulating free 
testosterone levels also have poor prognosis factors and 
higher tumor burden prior to treatment [28]. These findings 
reinforce the idea that low PCA3 levels in high grade PCa 
may reflect lower circulating androgen levels, leading to 
weaker AR activation and transcriptional activity. This 
suggests that PCA3 may act as a surrogate marker for 
serum testosterone.
Based on results presented in our study, PCA3 assays 
as currently formatted have limited utility in detecting men 
with higher grade disease. Even though such tools have 
shown to reduce number of biopsies, they have high rate 
of missing high grade disease due to low PCA3 levels. We 
have observed such a case recently, where a patient was 
negative for prostate cancer as assessed by urinary PCA3, 
but was later diagnosed to have very high grade disease 
(GS 9) and high Decipher metastasis risk. To overcome 
this limitation, recently developed commercial diagnostic 
tools have incorporated additional biomarkers like ERG 
[7], HOXC6, DLX1 [28]. Additional markers designed to 
detect higher grade disease and non-ERG tumors would 
likely improve the utility of the assay. This study suggests 
that next-generation diagnostic tools using PCA3 and ERG 
should incorporate additional biomarkers to ensure high 
grade disease is detected in low PCA3 and ERG-fusion 
negative samples.
The current study has some limitations. We 
acknowledge the majority of our analyses are based on 
tissue PCA3 whilst current PCA3 assays are urine based. 
We have generated preliminary data profiling gene 
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expression from a small number of urine samples (n=50) 
using the same Human Exon arrays (Supplementary Figure 
4). Even though the range of PCA3 expression is different 
in tumor tissue and urine samples, the PCA3 trend in 
urine sample is very similar to tissue PCA3 suggesting 
that results from this study may hold true when conducted 
in large number of urine sample. Additional studies are 
warranted to firmly establish the relationship between 
high grade prostate cancer and the utility of PCA3 score 
in urine-based diagnostic tests. Additional urine-based 
diagnostic tools that incorporates additional biomarkers 
are needed to overcome limitations of PCA3 assays.
MATERIALS AND METHODS
Study population
A total of 10,382 expression profiles from RP 
tissues, primarily with adverse pathology and other 
high risk features, and 1,694 profiles from initial biopsy 
tissues were obtained from the Decipher GRID™ prostate 
cancer database (NCT02609269). This cohort represents 
cases from multi-institutional retrospective cohorts 
(Supplementary Table 1) [2, 20, 21, 23, 29] with detailed 
clinical, pathological, treatment and outcomes data and 
de-identified, anonymized prospective cases with basic 
demographic and pathological data from clinical use of the 
Decipher test from RP and biopsy settings (Supplementary 
Table 2).
Tissue processing, microarray data 
preprocessing and PCA3 expression 
measurement
Specimen selection, RNA extraction, and Human 
Exon 1.0 ST Array hybridization was done in a Clinical 
Laboratory Improvement Amendments (CLIA/CAP)-
certified laboratory facility (GenomeDx Biosciences, 
San Diego, CA, USA) as previously described [30]. The 
Supplementary Material provides additional details. PCA3 
gene expression was summarized using the mean of the 5 
probe sets in the Human Exon 1.0 ST array that are falling 
in the PCA3 locus (Supplementary Figure 1) and corrected 
for batch effects using an empirical Bayes framework 
(ComBat in “sva” R package).
Statistical analysis
Statistical analyses were performed in R v3.2.2, and 
all tests were two-sided using a 5% significance level. 
Clinical variables were categorized as follows: Gleason 
Score (GS) was grouped into ISUP groups: Group 1(GS 
6), Group 2(3+4), Group 3(4+3), Group 4(8), Group 
5 (9-10). Pre-operative PSA was categorized into low 
(≤10 ng/ml) and high (>10 ng/ml) groups. The following 
variables were binary (present vs. absent): Extra-prostatic 
extension (EPE), seminal vesicle invasion (SVI), surgical 
margins (SM) and lymph node invasion (LNI). Fisher’s 
exact test was used to study the association between 
categorical variables. PCA3 expression was dichotomized 
using the optimal cut-off value splitting PCA3 into low 
(≤1.3) vs high (>1.3) using the “optimize R” package 
that is based on combination of golden section search 
and successive parabolic interpolation. Correlations of 
PCA3 expression with pathologic stage and pathologic 
Gleason score were computed using Spearman’s rank 
correlation. Univariable (UVA) and multivariable (MVA) 
logistic regression analyses were used to evaluate the 
association of PCA3 and clinical variables. Kaplan Meier 
curves stratified by PCA3 expression levels (low vs. high) 
were constructed to obtain metastasis-free survival rates 
after RP. Cox proportional hazards analysis were used to 
determine the performance of PCA3 in predicting risk of 
metastasis. In time to event analyses, event times were 
defined as the time from RP to metastasis. Decipher risk 
categories, an extensively validated measure of prostate 
cancer metastasis risk [20, 22, 23, 29–32], were used as 
a surrogate for metastasis (low, intermediate vs high risk) 
in the prospective cohort where no metastasis outcomes 
were available.
CONCLUSION
In conclusion, we report that high levels of PCA3 
may be a poor predictor of high grade disease in the 
initial biopsy setting and low PCA3 expression in primary 
tumors may portend a poor prognosis. We observed a 
unique bimodal distribution for PCA3, where low levels 
of PCA3 were associated with high grade disease in 
urine, tissue biopsy, and tissue RP, and poor survival and 
increased rates of metastasis after RP. To our knowledge, 
this is the largest study characterizing the associations 
between PCA3 RNA from RP tissues with pathological 
variables at RP and clinical outcome. Results in this study 
suggest that sole use of PCA3 as a stand-alone marker for 
prostate cancer may provide false negatives for patients 
with higher grade disease and urologists should be warned 
of this limitation.
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